Nanoviricides (NNVC) Current Assets (2011 - 2026)
Nanoviricides (NNVC) posted Current Assets of $3.4 million for Q1 2026, down 36.22% sequentially from $5.3 million in Q4 2025, and up 23.86% YoY from $2.7 million in Q1 2025.
Nanoviricides (NNVC) Current Assets (2011 - 2026) Analysis & Trends
Nanoviricides has reported Current Assets for 16 years, with the latest figure at $3.4 million in Q1 2026.
- Quarterly Current Assets rose 23.86% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 23.86% YoY) and the FY2025 annual result came in at $1.7 million, down 66.39% from the prior year.
- Current Assets retreated to $3.4 million in Q1 2026 per NNVC's latest filing, from $5.3 million in the prior quarter.
- Over five years, Current Assets peaked at $15.9 million in Q1 2022 and troughed at $1.3 million in Q3 2025.
- A 5-year average of $6.9 million and a median of $5.3 million in 2025 frame the typical range for Current Assets.
- The widest YoY moves for Current Assets: up 30.08% in 2025, down 69.01% in 2025.
- Over 5 years, Current Assets stood at $11.6 million in 2022, then plunged by 53.97% to $5.3 million in 2023, then retreated by 23.43% to $4.1 million in 2024, then jumped by 30.08% to $5.3 million in 2025, then tumbled by 36.22% to $3.4 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $3.4 million, $5.3 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | Nanoviricides | 29.50 Mn | 26.28 Mn | - | 3.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.38 Mn |
| Dec 31, 2025 | 5.30 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 2.73 Mn |
| Dec 31, 2024 | 4.07 Mn |
| Sep 30, 2024 | 4.04 Mn |
| Jun 30, 2024 | 4.97 Mn |
| Mar 31, 2024 | 3.52 Mn |
| Dec 31, 2023 | 5.32 Mn |
| Sep 30, 2023 | 7.14 Mn |
| Jun 30, 2023 | 8.45 Mn |
| Mar 31, 2023 | 9.93 Mn |
| Dec 31, 2022 | 11.55 Mn |
| Sep 30, 2022 | 13.15 Mn |
| Jun 30, 2022 | 14.42 Mn |
| Mar 31, 2022 | 15.95 Mn |
| Dec 31, 2021 | 17.52 Mn |
| Sep 30, 2021 | 19.89 Mn |
| Jun 30, 2021 | 20.82 Mn |